Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays

Documenti analoghi

• Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
  di: Daniel Kraemmer, et al.
  Pubblicazione: (2025)
• Monitoring Extended Half‐Life Factor VIII and IX Concentrates: Performance in Routine Clotting‐and Thrombin Generation Assays
  di: An K. Stroobants, et al.
  Pubblicazione: (2026)
• Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update
  di: Carmen Escuriola Ettingshausen, et al.
  Pubblicazione: (2025)
• TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
  di: Kagehiro Amano, et al.
  Pubblicazione: (2025)
• The First Three Japanese Haemophilia A Patients in Whom Factor VIII Inhibitors Were Observed During Prophylactic Treatment With Efanesoctocog Alfa
  di: Tazuko Tokugawa, et al.
  Pubblicazione: (2025)